These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
207 related articles for article (PubMed ID: 20101224)
1. Rac1 is required for oncolytic NDV replication in human cancer cells and establishes a link between tumorigenesis and sensitivity to oncolytic virus. Puhlmann J; Puehler F; Mumberg D; Boukamp P; Beier R Oncogene; 2010 Apr; 29(15):2205-16. PubMed ID: 20101224 [TBL] [Abstract][Full Text] [Related]
2. Analysis of three properties of Newcastle disease virus for fighting cancer: tumor-selective replication, antitumor cytotoxicity, and immunostimulation. Fournier P; Bian H; Szeberényi J; Schirrmacher V Methods Mol Biol; 2012; 797():177-204. PubMed ID: 21948477 [TBL] [Abstract][Full Text] [Related]
3. Host mediated anti-tumor effect of oncolytic Newcastle disease virus after locoregional application. Apostolidis L; Schirrmacher V; Fournier P Int J Oncol; 2007 Nov; 31(5):1009-19. PubMed ID: 17912426 [TBL] [Abstract][Full Text] [Related]
4. Selective oncolytic effect of an attenuated Newcastle disease virus (NDV-HUJ) in lung tumors. Yaacov B; Eliahoo E; Lazar I; Ben-Shlomo M; Greenbaum I; Panet A; Zakay-Rones Z Cancer Gene Ther; 2008 Dec; 15(12):795-807. PubMed ID: 18535620 [TBL] [Abstract][Full Text] [Related]
5. Generation of a recombinant oncolytic Newcastle disease virus and expression of a full IgG antibody from two transgenes. Pühler F; Willuda J; Puhlmann J; Mumberg D; Römer-Oberdörfer A; Beier R Gene Ther; 2008 Mar; 15(5):371-83. PubMed ID: 18200068 [TBL] [Abstract][Full Text] [Related]
6. Newcastle disease virus as an oncolytic agent. Ravindra PV; Tiwari AK; Sharma B; Chauhan RS Indian J Med Res; 2009 Nov; 130(5):507-13. PubMed ID: 20090097 [TBL] [Abstract][Full Text] [Related]
7. Gene expression profiling in PC12 cells infected with an oncolytic Newcastle disease virus strain. Balogh A; Bátor J; Markó L; Németh M; Pap M; Sétáló G; Müller DN; Csatary LK; Szeberényi J Virus Res; 2014 Jun; 185():10-22. PubMed ID: 24637408 [TBL] [Abstract][Full Text] [Related]
8. Human tumor cell modification by virus infection: an efficient and safe way to produce cancer vaccine with pleiotropic immune stimulatory properties when using Newcastle disease virus. Schirrmacher V; Haas C; Bonifer R; Ahlert T; Gerhards R; Ertel C Gene Ther; 1999 Jan; 6(1):63-73. PubMed ID: 10341877 [TBL] [Abstract][Full Text] [Related]
9. Viability reduction and Rac1 gene downregulation of heterogeneous ex-vivo glioma acute slice infected by the oncolytic Newcastle disease virus strain V4UPM. Mustafa Z; Shamsuddin HS; Ideris A; Ibrahim R; Jaafar H; Ali AM; Abdullah JM Biomed Res Int; 2013; 2013():248507. PubMed ID: 23586025 [TBL] [Abstract][Full Text] [Related]
10. Construction of recombinant Newcastle disease virus Italien strain for oncolytic virotherapy of tumors. Wei D; Sun N; Nan G; Wang Y; Liu HQ; Peeters B; Chen ZN; Bian H Hum Gene Ther; 2012 Jul; 23(7):700-10. PubMed ID: 22372930 [TBL] [Abstract][Full Text] [Related]
11. Exploring host factors that impact reovirus replication, dissemination, and reovirus-induced cell death in cancer versus normal cells in culture. Shmulevitz M; Lee PW Methods Mol Biol; 2012; 797():163-76. PubMed ID: 21948476 [TBL] [Abstract][Full Text] [Related]
12. In vivo efficacy of systemic tumor targeting of a viral RNA vector with oncolytic properties using a bispecific adapter protein. Bian H; Wilden H; Fournier P; Peeters B; Schirrmacher V Int J Oncol; 2006 Dec; 29(6):1359-69. PubMed ID: 17088973 [TBL] [Abstract][Full Text] [Related]
13. [Progress in using Newcastle disease virus for tumor therapy: a review]. Wu Y; Hao J; Li D Sheng Wu Gong Cheng Xue Bao; 2010 Aug; 26(8):1031-6. PubMed ID: 21090105 [TBL] [Abstract][Full Text] [Related]
14. Malignant peripheral nerve sheath tumors with high and low Ras-GTP are permissive for oncolytic herpes simplex virus mutants. Mahller YY; Rangwala F; Ratner N; Cripe TP Pediatr Blood Cancer; 2006 Jun; 46(7):745-54. PubMed ID: 16124003 [TBL] [Abstract][Full Text] [Related]
15. ISG12a mediates cell response to Newcastle disease viral infection. Liu N; Long Y; Liu B; Yang D; Li C; Chen T; Wang X; Liu C; Zhu H Virology; 2014 Aug; 462-463():283-94. PubMed ID: 24999841 [TBL] [Abstract][Full Text] [Related]
16. Recombinant oncolytic Newcastle disease virus displays antitumor activities in anaplastic thyroid cancer cells. Jiang K; Song C; Kong L; Hu L; Lin G; Ye T; Yao G; Wang Y; Chen H; Cheng W; Barr MP; Liu Q; Zhang G; Ding C; Meng S BMC Cancer; 2018 Jul; 18(1):746. PubMed ID: 30021550 [TBL] [Abstract][Full Text] [Related]
17. Isolation of a human melanoma adapted Newcastle disease virus mutant with highly selective replication patterns. Ahlert T; Schirrmacher V Cancer Res; 1990 Sep; 50(18):5962-8. PubMed ID: 2203523 [TBL] [Abstract][Full Text] [Related]
18. A mutant type 2 herpes simplex virus deleted for the protein kinase domain of the ICP10 gene is a potent oncolytic virus. Fu X; Tao L; Cai R; Prigge J; Zhang X Mol Ther; 2006 May; 13(5):882-90. PubMed ID: 16569513 [TBL] [Abstract][Full Text] [Related]
19. Use of reverse genetics to enhance the oncolytic properties of Newcastle disease virus. Vigil A; Park MS; Martinez O; Chua MA; Xiao S; Cros JF; Martínez-Sobrido L; Woo SL; García-Sastre A Cancer Res; 2007 Sep; 67(17):8285-92. PubMed ID: 17804743 [TBL] [Abstract][Full Text] [Related]
20. Newcastle disease virus LaSota strain kills human pancreatic cancer cells in vitro with high selectivity. Walter RJ; Attar BM; Rafiq A; Tejaswi S; Delimata M JOP; 2012 Jan; 13(1):45-53. PubMed ID: 22233946 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]